RESOURCES

Where research scientists come to find up to date resources on antibody discovery against challenging membrane protein targets.

Category: news

RVP Users’ Group: Omicron RVPs and their role in safe neutralization assessment | February 15th, 11am ET

Join this users’ group to learn about our extensive catalog of SARS-CoV-2 Reporter Virus Particles (RVPs, pseudotyped viruses) including Omicron, and how they enable researchers to rapidly test neutralization titers of antibodies and vaccine sera in a safe BSL-2 environment.

Watch video

We will discuss:

  • Integral Molecular’s extensive catalog of >65 SARS-CoV-2 Reporter Virus Particles (RVPs) and how they can help you safely assess virus neutralization
  • New offerings including Omicron RVPs (available now), and specialized reagents coming soon
  • Case studies of antibodies that bind Spike but permit infection, highlighting the importance of assaying neutralization



Integral Molecular Adds Transgenic Humanized Mice to Expand its MPS Antibody Discovery Platform Through a Partnership with Alloy Therapeutics

PHILADELPHIA — Integral Molecular, the leader in discovering antibodies against multipass membrane proteins, has entered into an agreement to leverage Alloy Therapeutics’ transgenic humanized ATX-GxTM mice as an added strategy to rapidly isolate fully human monoclonal antibodies using Integral Molecular’s MPS Antibody Discovery platform. ATX-GxTM is a suite of immunologically robust transgenic mice that produce antibodies with fully human sequences. Lacking non-human sequences that can trigger severe immune side-effects, the resulting antibodies have high developability.

Integral Molecular’s MPS platform is optimized for discovering MAbs against structurally complex membrane proteins, a valuable group of therapeutic targets. With a 95% success rate in delivering antibodies targeting complex membrane proteins, MPS successes include antibodies recently licensed to Context Therapeutics (Nasdaq: CNTX) and AstraZeneca (LSE/STO/Nasdaq: AZN). Alloy’s ATX-GxTM mice complement Integral Molecular’s proprietary humanized chicken antibody technology (hCAT) now allowing partners to choose their preferred method to isolate fully humanized antibodies.

“We look forward to working with Integral Molecular as a Certified Service Provider to make our antibody discovery platform available to more drug discovery teams,” said Heather Schwoebel, Alloy Therapeutics’ Chief Operating Officer and Head of Business Development. “By harnessing Integral’s technologies, we have already seen exceptional immune responses to difficult targets, such as GPCRs, in the Alloy mice.”

Partners interested in antibody discovery should contact Integral Molecular.

About Integral Molecular

Integral Molecular (integralmolecular.com) is the industry leader in developing and applying innovative technologies that advance the discovery of therapeutics against difficult protein targets. With 20 years of experience focused on membrane proteins and antibodies, Integral Molecular’s technologies have been integrated into the drug discovery pipelines of over 400 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, autoimmune disorders, and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue viruses.

About Alloy Therapeutics

Alloy Therapeutics (alloytx.com) is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners, Alloy democratizes access to tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics. The company facilitates affordable, non-exclusive access to the entire drug discovery community from academic scientists, small and medium biotech, to the largest biopharma. Alloy’s lead offering, the ATX-Gx™ platform, is a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Alloy is headquartered in Boston, MA with labs in Cambridge, UK; Basel, CH; San Francisco, CA; and Athens, GA.

 

Integral Molecular Adds Omicron to its Panel of 68 SARS-CoV-2 Reporter Virus Variants to Assess the Effectiveness of Vaccines and Therapeutics

PHILADELPHIA — Integral Molecular has developed the most extensive catalog of 68 variant SARS-CoV-2 Reporter Virus Particles (RVPs), now including Omicron, allowing researchers to safely test the ability of vaccines and therapeutic antibodies to neutralize this yet uncharacterized viral threat.

Integral Molecular’s RVPs are “pseudoviruses” that lack the viral components required to cause disease. SARS-CoV-2 RVPs are safe to use under standard laboratory conditions, are amenable to high-throughput screening, and eliminate the need to use live virus for testing the neutralizing effects of antibodies and vaccines. The company has developed SARS-CoV-2 RVPs for all variants of concern and interest as classified by the Center for Disease Control (CDC) and World Health Organization (WHO).

“With at least 32 mutations in the Omicron Spike protein, scientists are racing to understand how well vaccines and therapeutic antibodies will protect against this variant,” said Hayley Crawford, PhD, Virologist at Integral Molecular. “Omicron RVPs will allow scientists to safely and quickly assess the neutralizing abilities of these treatments to determine how likely they are to be effective.” Integral Molecular is the industry leader in supplying reporter viruses to the biopharmaceutical industry for vaccine testing, drug discovery, and research for over 10 years.

The FDA has requested that developers of therapeutic antibodies keep abreast of new circulating variants and provide data about the effectiveness of their antibodies in neutralizing them. Variant SARS-CoV-2 RVPs have been used to extensively profile antibodies, including Immunome’s 3-antibody cocktail IMM-BCP-01, which was recently submitted to the FDA as an Investigational New Drug (IND). Immunome reports that this powerful cocktail neutralized all variant RVPs that were tested, including Delta, Alpha, Beta and Gamma (Nikitin et al., bioRxiv, 2021).

To order Omicron SARS-CoV-2 RVPs for testing antibodies or vaccine responses please contact Integral Molecular at info@integralmolecular.com.

About Integral Molecular

Integral Molecular (integralmolecular.com) is the industry leader in developing and applying innovative technologies that advance the discovery of therapeutics against difficult protein targets. With 20 years of experience focused on membrane proteins and antibodies, Integral Molecular’s technologies have been integrated into the drug discovery pipelines of over 400 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, autoimmune disorders, and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue viruses.

 

Integral Molecular Enters into Antibody License Agreement with AstraZeneca for Oncology Therapeutics

PHILADELPHIA —Integral Molecular, an industry leader in developing antibodies against membrane proteins, announced today that it entered into an exclusive worldwide antibody license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop therapeutics for multiple cancers.  

Under the terms of the agreement, Integral Molecular will provide an exclusive license to AstraZeneca for a collection of highly specific monoclonal antibodies for use in oncology. AstraZeneca will be solely responsible for all research, development, and commercial activities.  

This agreement with Integral Molecular will allow AstraZeneca to generate additional novel cancer therapies and advance our goal of delivering personalised treatments to improve patient outcomes,” said Mark Cobbold, VP, Discovery, Oncology R&D at AstraZeneca. “These antibodies can be incorporated into a number of therapeutic modalities and align with AstraZeneca’s ongoing pursuit of high-quality innovation to deliver life-changing treatments that increase the potential for cure.” 

“Specificity is incredibly important for therapies designed to eliminate cancer cells, since mistargeting can have serious safety ramifications for patients,” said Benjamin Doranz, CEO and co-founder of Integral Molecular. “Our program has produced antibodies with picomolar affinity and high specificity even against conserved targets that have proven difficult to generate antibodies against. The specificity of these antibodies is a testament to the dedication and efforts of our talented team.” 

The antibodies licensed by AstraZeneca were discovered and characterized using Integral Molecular’s platforms designed to yield antibodies against structurally complex membrane proteins. Together, the MPS Antibody Discovery platform, Lipoparticles, Membrane Proteome Array, and Shotgun Mutagenesis Epitope Mapping technologies were used to generate diverse antibodies with exceptional specificity. 

About Integral Molecular 

Integral Molecular (integralmolecular.com) is the industry leader in developing and applying innovative technologies that advance the discovery of therapeutics against difficult protein targets. With 20 years of experience focused on membrane proteins and antibodies, Integral Molecular’s technologies have been integrated into the drug discovery pipelines of over 400 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, autoimmune disorders, and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue viruses. 

Integral Molecular and Integrated BioTherapeutics Collaborate to Engineer Broadly Protective Ebolavirus Vaccines

PHILADELPHIA – A collaboration between Integral Molecular and Integrated BioTherapeutics (IBT), two biotechnology companies with deep expertise in virology, has resulted in engineered proteins that may enable next-generation vaccines with broad protection against Ebola and related viruses. 

With access to neutralizing Ebola antibodies discovered by IBT, Integral Molecular used Shotgun Mutagenesis—part of its GeneCanvas protein engineering platform—to identify mutations in the Ebola virus envelope glycoprotein that make it more visible to the immune system. Recently issued as a patent by the US Patent and Trademark Office (US 11,135,280 B2), the engineered proteins have the potential to transform vaccine design strategies to deliver efficient protection against Ebola virus and additional related viruses. Ebola virus causes a severe disease with 50% mortality rate, and available vaccines may not protect against other related species of Ebolavirus, because of the differences among their envelope glycoproteins. 

“Having battled numerous viral outbreaks and now a global pandemic, the scientific community is more attuned than ever to the urgency of sharing knowledge and resources to fight viral threats and intractable diseases,” said M. Javad Aman, Ph.D., President of IBT. “We hope that the confluence of Integral Molecular’s protein engineering talent and mechanistic insights from IBT’s antibodies will advance a vaccine that eradicates future threats from this deadly virus.” 

Integral Molecular’s GeneCanvas protein engineering platform has been used to successfully optimize hundreds of antibodies, viral proteins, and transgenes for affinity, activity, and specificity. 

About Integral Molecular 

Integral Molecular (www.integralmolecular.com) is the industry leader in discovering and characterizing therapeutic antibodies against membrane proteins, an important group of drug targets found on the surfaces of cells and viruses. Integral Molecular’s technologies have been integrated into the drug discovery pipelines of over 400 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, autoimmune disorders, and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue virus. 

About Integrated BioTherapeutics 

IBT develops vaccines and immunotherapies for bacterial and viral infectious diseases. The Company’s lead vaccine product, IBT-V02 is a first-in-class multi-component vaccine against Staphylococcus aureus. Supported by CARB-X and by Novo Holdings’ Repair Impact Fund, IBT-V02 is currently undergoing cGMP manufacturing and IND-enabling studies, with initiation of clinical trials anticipated in late 2021. IBT’s portfolio also includes novel monoclonal antibody therapeutics for Ebola and Marburg viruses. Learn more about IBT’s pipeline at www.integratedbiotherapeutics.com. 

Webinar: Combatting SARS-CoV-2 Variants: Neutralization Testing from Alpha to Mu

Date: November 30, 2021

Watch Video

COVID-19 has united scientists with a shared mission, sense of collaboration, and urgency. Global lab meetings, prompt sharing of scientific results, and resource repositories will continue to advance the development of vaccines and therapeutics.

Join this GEN webinar to learn how SARS-CoV-2 Reporter Virus Particles (RVPs, pseudotyped viruses) enable researchers to rapidly test neutralization titers of antibodies and vaccinee sera in a safe BSL-2 environment. Additionally, our panelists will describe how access to Integral Molecular’s extensive collection of >65 SARS-CoV-2 variant RVPs enables them to test against emerging mutants and meet the most recent FDA recommendations for variant testing of vaccines and therapeutic antibodies.

Philadelphia Biotech Integral Molecular Celebrates 20 Years of Innovation, Growth, and Community

Integral LeadershipPHILADELPHIA — Integral Molecular, a founding member of Philadelphia’s biotech community, celebrates its 20th anniversary as a leader in antibody discovery and virology. With a mission to develop and apply innovative technologies that advance therapeutic discovery, the company has recently been at the forefront of Pennsylvania’s contribution to the fight against COVID-19.

“Integral Molecular is a long-time leader of Philadelphia’s biotech community and we are thrilled to see the company’s continued progress and expansion in our city,” said Philadelphia Mayor Jim Kenney while celebrating this milestone. He additionally applauded the company’s hard work and contribution to vaccine research.

Integral Molecular was co-founded by Drs. Benjamin Doranz, Sharon Willis and Joseph Rucker who share a long history that began as trainees at the University of Pennsylvania. Still working together, they steer the company into its third decade and actively shape its scientific direction.

“We started the company with a few interesting ideas and a small incubator space at the University City Science Center in Philadelphia,” said Benjamin Doranz, CEO of Integral Molecular. Twenty years later, we are just as passionate about science and creating solutions, but now with the creativity of a larger team and over 400 customers around the world.”

“Integral Molecular is proudly committed to the local community,” said Sharon Willis, Vice-President. “We have an outstanding team of dedicated people with a desire to make a difference, and cultivate the next generation of scientists, including many from our immediate neighborhood.” Integral Molecular works with students, artists, and workforce development initiatives in West Philadelphia. This includes the University City Science Center’s BioArt residency program, BULB lab basics program, FirstHand STEM program, and Wistar Institute’s Biomedical Technician Training Program.

With two research facilities in University City, Integral Molecular is actively planning its next expansion in Philadelphia’s uCity Square.

About Integral Molecular

Integral Molecular (integralmolecular.com) is the industry leader in developing and applying innovative technologies that advance the discovery of therapeutics against difficult protein targets. With 20 years of experience focused on membrane proteins and antibodies, Integral Molecular’s technologies have been integrated into the drug discovery pipelines of over 400 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, autoimmune disorders and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue viruses.

Webinar: Comprehensive Specificity Profiling of Antibody-Based Therapeutics Using the Membrane Proteome Array

Webinar Description:

Rigorous specificity analysis is critical for drug development success, as even minimal off-target binding can lead to preclinical failures or serious adverse effects in clinical trials. Long believed to be highly specific, recent clinical data and our own profiling of lead panels indicate that antibodies frequently (~25%) display cross-reactivity.

Specificity profiling is an FDA requirement for monoclonal antibodies (MAbs) and other antibody-based biotherapeutics, such as CAR-T cells. Tissue cross-reactivity (TCR) studies have traditionally been used to screen for off-target binding. However, TCR studies are poorly predictive of in vivo safety and toxicity and the results of TCR studies have limited influence on the development strategy. As a result, cell-based arrays are increasingly used to fulfill specificity profiling and regulatory requirements.

Integral Molecular has developed the Membrane Proteome Array (MPA) as a novel approach to test the specificity of biotherapeutics and identify any off-target interactions. The MPA is a cell-based array containing the largest comprehensive library of human membrane proteins. With 6,000 membrane proteins presented in their native conformation, the MPA encompasses 94% of the human membrane proteome. The MPA platform is highly sensitive, using high-throughput flow cytometry to identify binding interactions on a protein level, and has emerged as the leading solution for antibody specificity profiling.

Learning Objectives:

With a focus on specificity screening, this webinar assembles experts in antibody discovery and development and features presentations from Integral Molecular, Novartis, and Abound Bio.

  • Understand how Integral Molecular’s MPA is used to select leads that do not display off-target binding liabilities
  • Learn how cell-array data, such as the MPA screen, supports IND submissions either without or in conjunction with traditional tissue cross-reactivity studies
  • Discover how the MPA was used to rapidly evaluate the specificity of a novel antibody-based SARS-CoV-2 therapeutic

Watch video

Speakers:

Rachel Fong

Rachel Fong
Senior Project Leader
Alliance Management, Integral Molecular

Rachel Fong is Integral Molecular’s Senior Alliance Manager, with over 10 years of experience at the company. Rachel manages relationships with customers, collaborators, and partners, for MPA projects. As a founding member of the scientific team that launched this platform, she brings a unique perspective that helps guide partners from initial discussions to successful project completion. Rachel joined Integral Molecular in 2010 and is a co-author on over a dozen publications. In this webinar, Rachel will give an overview of the Membrane Proteome Array (MPA) technology and its uses. She will briefly discuss case studies of clinical MAb safety failures that could have been averted by prudent specificity testing on Integral Molecular’s MPA. She will also introduce alternative uses of the MPA, such as functional screening and target discovery.

Timothy MacLachlan

Timothy MacLachlan, PhD, DABT
Executive Director, PCS TA Head – Cardiovascular and Metabolism
Novartis Institutes for BioMedical Research

Dr. MacLachlan is currently an Executive Director in the department of Preclinical Safety (PCS) at the Novartis Institutes for Biomedical Research (NIBR). He serves as the therapeutic area head within PCS for the Cardiovascular/Metabolic Disease Area of NIBR. He also oversees safety assessment for biotherapeutics and gene and cell therapies within the NIBR portfolio. Dr. MacLachlan has founded, led and participated in several industry and academic consortia focused on the nonclinical development of biotherapeutics and cell/gene therapies for organizations such as BIO, EFPIA, PhRMA, SOT and ASGCT. Dr. MacLachlan received his PhD from Thomas Jefferson University and did his postdoctoral research in the Howard Hughes Medical Institute at the University of Pennsylvania. In this webinar, Dr. MacLachlan will give an introduction on specificity profiling of biotherapeutics for regulatory submissions. He will discuss results of a recent survey of industry developers on their methods used for profiling specificity, comparing traditional immunohistochemistry Tissue Cross-Reactivity (TCR) studies with emerging cell array technologies such as the MPA.

Dimiter Dimitrov

Dimiter Dimitrov, PhD, ScD
EVP and CSO
Abound Bio

Dr. Dimitrov is the Executive Vice President and Chief Scientific Officer of Abound Bio, a biotechnology company dedicated to developing novel antibody-based biological therapeutics for cancer and infectious diseases. Dr. Dimitrov is a world-leading antibody scientist and engineer with more than 30 years of experience. He co-founded Abound Bio in 2019 and is also currently a Professor of Medicine and Director of the Center for Antibody Therapeutics at the University of Pittsburgh Medical School. Prior to this, he was tenured Senior Investigator in the National Cancer Institute and appointed the Senior Biomedical Research Service at the NIH. Dr. Dimitrov received his PhD from the University of Sofia, Sofia, Bulgaria, and a ScD from the Bulgarian Academy of Sciences. He has over 400 publications cited more than 30,000 times, 100 patents, and multiple discoveries leading to one therapeutic antibody approval, several others in multiple clinical trials, and many more in preclinical development. In the webinar, Dr. Dimitrov will discuss Abound Bio’s antibody engineering project for SARS-CoV-2. Their therapeutic compound, a bivalent VH, VH-Fc ab8, potently neutralized SARS-CoV-2 in animals and showed high specificity with no off-targets identified by screening on the MPA. Their findings were published in Cell in September 2020 and this was one of the first potential therapeutics identified for COVID-19 back in February 2020.

Integral Molecular’s Extensive Collection of SARS-CoV-2 Reporter Virus Variants Supports the Clinical Development of Vaccines and MAbs Against Coronavirus

PHILADELPHIA — To aid in the clinical development of new vaccines and monoclonal antibodies (MAbs) effective against emerging and highly infectious coronavirus variants, Integral Molecular has produced the most extensive catalog of SARS-CoV-2 pseudotyped reporter virus particles (RVPs), currently over 65 variants, which enables neutralizing antibodies or serum to be assessed in accordance with recent FDA guidances.

Integral Molecular has developed SARS-CoV-2 RVPs for all variants of concern and interest, including Delta, Delta Plus, Lambda, and Gamma, as classified by the Center for Disease Control (CDC) and World Health Organization (WHO). The company’s scientific team constantly monitors a range of sources to identify new SARS-CoV-2 variants, alert customers, and rapidly make RVPs available to researchers.

The FDA recognizes that current COVID-19 vaccines and therapeutic MAbs may provide reduced protection against emerging variants and has issued guidance for developers testing the efficacy of vaccines and MAbs against such variants. The recognition that a neutralizing antibody response is an important correlate of protection for COVID-19 vaccines further highlights the importance of studying serum neutralization using live virus or the safer alternative, RVPs.

Integral Molecular’s RVPs are “pseudoviruses” that lack the viral components required to cause disease and so can be safely handled under standard laboratory conditions. This greatly facilitates the testing of hundreds or thousands of samples from clinical trials, where RVPs are used to assess neutralizing antibodies against the virus.

“Virology is at the core of our company,” said Benjamin Doranz, CEO of Integral Molecular. “Throughout the last 20 years we have been developing technologies using viral components and have produced large-scale batches of quality-controlled RVPs as a critical reagent to support clinical trials. In the midst of this pandemic, we are proud to support the fight against COVID-19.”

Partners interested in using SARS-CoV-2 RVPs for vaccine or antibody development should contact Integral Molecular.

About Integral Molecular

Integral Molecular (integralmolecular.com) is the industry leader in developing and applying innovative technologies that advance the discovery of therapeutics against difficult protein targets. With 20 years of experience focused on membrane proteins and antibodies, Integral Molecular’s technologies have been integrated into the drug discovery pipelines of over 400 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, autoimmune disorders and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue viruses.